StockData

Viking Therapeutics vs vTv Therapeutics

VKTX and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VKTX and VTVT compare

Viking Therapeutics is the larger company, worth 50 times as much as vTv Therapeutics ($3.4B against $68.4M).

vTv Therapeutics scores higher on the StockData Score (11 against 5 for Viking Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVKTXVTVT
Size and price
Market cap$3.4B$68.4M
Share price$26.88$17.29
Change, 1 year−31.3%−43.9%
Change, 5 years400%−67.7%
Beta (5Y)1.240.08
Employees5326
StockData Score
Total score511 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S–1.9×
P/B5.8×0.9× (better)
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)–216600%
Profitability
Operating margin–−25.1%
Net margin–−12.9%
Return on equity−96.4%−11.7% (better)
Financial health
Debt / equity0.000.00
Current ratio7.2712.48 (better)
Altman Z-score2.25 (better)0.71
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions59.4%40.6%
Held by insiders2.7%26.3%
Insider net buying, 12 months−$18.2M–
Short interest, % of float19.5%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.